IP Library Granted Patent US 9,757,329
Granted Patent B2
US 9,757,329 · App. 14/810,975 · Granted Sep 12, 2017

Pharmaceutical composition comprising botulinum, a non ionic surfactant, sodium chloride and sucrose

Inventors: Paul Webb (Wrexham, GB); Mary White (Wrexham, GB); Julie Partington (Wrexham, GB)
Assignee: Ipsen Biopharm Limited
A61K9/0019A61K9/19A61K38/4886A61K38/4893A61K47/26C12Y304/24069
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,757,329
App. No.
14/810,975
Granted
Sep 12, 2017
Kind
B2
Abstract

The invention relates to a solid or liquid pharmaceutical composition comprising botulinum neurotoxin complex (type A, B, C, D, E, F or G) or high purity botulinum neurotoxin (type A, B, C, D, E, F or G), and a surfactant. In particular the invention relates to a solid or liquid pharmaceutical composition comprising a crystalline agent.

Claims (25)

1. A solid or liquid pharmaceutical composition consisting of:

(a) botulinum neurotoxin complex of type A, B, C, D, E, F or G, or a high purity botulinum neurotoxin of type A, B, C, D, E, F or G;

(b) a non-ionic surfactant;

(c) sodium chloride;

(d) a buffer capable of maintaining an aqueous solution at a pH of 5.5 to 7.5;

(e) a disaccharide; and

(f) when the composition is liquid, water,

wherein the composition does not contain albumin or polysaccharides.

2. The composition of claim 1 , wherein the botulinum neurotoxin complex is type A.

3. The composition of claim 1 , wherein the high purity botulinum neurotoxin is type A.

4. The composition of claim 1 , wherein the botulinum neurotoxin is present at 50 to 3,000 LD50 units.

5. The composition of claim 1 , wherein the non-ionic surfactant is a polysorbate.

6. The composition of claim 5 , wherein the polysorbate is polyoxyethylene (20) sorbitan monooleate.

7. The composition of claim 1 , wherein the disaccharide is sucrose, trehalose or lactose.

8. The composition of claim 7 , wherein the disaccharide is sucrose.

9. The composition of claim 1 , wherein the buffer is succinate or histidine.

10. The composition of claim 9 , wherein the buffer is histidine.

11. The composition of claim 1 , wherein the buffer is capable of maintaining an aqueous solution at a pH of 5.8 to 7.0.

12. The composition of claim 1 , wherein the composition is a solid pharmaceutical composition.

13. The composition of claim 1 , wherein the composition is a liquid pharmaceutical composition.

14. The composition of claim 13 , wherein the non-ionic surfactant is present in an amount of from above critical micellar concentration to 1% v/v of the total volume of the composition.

15. The composition of claim 13 , wherein the non-ionic surfactant is polysorbate 80 and is present in an amount of from 0.005% to 0.02% v/v of the total volume of the composition.

16. The composition of claim 13 , wherein the concentration of sodium chloride is from 0.1 to 0.5 M.

17. The composition of claim 13 , wherein the disaccharide is present in a concentration of from 5 to 50 mM.

18. The composition of claim 13 , wherein the concentration of the buffer is from 1 to 50 mM.

Assignments (3)
CHANGE OF NAME Recorded Dec 29, 2015
From: IPSEN LIMITED
To: IPSEN DEVELOPMENTS LIMITED
Reel/Frame 037377/0993 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 28, 2015
From: WEBB, PAUL; WHITE, MARY; PARTINGTON, JULIE
To: IPSEN LIMITED
Reel/Frame 037363/0473 →
CHANGE OF NAME Recorded Aug 28, 2015
From: IPSEN DEVELOPMENTS LIMITED
To: IPSEN BIOPHARM LIMITED
Reel/Frame 036450/0225 →
Priority Claims (1)
GB 0415491.0 · Jul 12, 2004 · national
Continuity (2)
Continuation 11632156
Related Publication 20150328293A1 · Nov 19, 2015